AHA Late-Breaker - Rexlemestrocel Improves Cardiac Outcomes
Filed with ASX · · 3 pages · English
Melbourne, Australia; November 15, and New York, USA; November 14, 2021: Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that results from the randomized, controlled Phase 3 trial of rexlemestrocel-L in 565 patients with New York Heart Association (NYHA) class II and class III chronic heart failure (CHF) with reduc
Earlier from Mesoblast
- MSB Annual Financial Results and Operational Progress
- Mesoblast Update on Chronic Low Back Pain Program
- MSB Reports Q3 Financial Results and Operational Highlight
- COVID ARDS Trial Topline 60-Day Results
- Mesoblast Raises US$110M Led By US Strategic Investor Group
Later from Mesoblast
- MSB and Oaktree Conclude Refinancing of Senior Debt Facility
- Update on Novartis Agreement
- FDAs OTAT Agrees to Primary Endpoint for Back Pain
- Appendix 4C Quarterly Activity Report
- Ulcerative Colitis & Crohns Results Presented at ECCO
Follow Mesoblast into a list and get an email when it puts out news.
Follow Mesoblast